Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CMPS Stock Forecast 2026-2027
$13.39
Current Price
$1.81B
Market Cap
Buy 15
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CMPS Price Targets
+422.8%
To High Target of $70.00
+56.8%
To Median Target of $21.00
+27.0%
To Low Target of $17.00
CMPS Price Momentum
-4.2%
1 Week Change
+13.6%
1 Month Change
+276.1%
1 Year Change
+94.1%
Year-to-Date Change
-13.1%
From 52W High of $15.40
+288.1%
From 52W Low of $3.45
📊 TOP ANALYST CALLS
Did CMPS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Compass Pathways is one of their latest high-conviction picks.
Latest CMPS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CMPS has a bullish consensus with a median price target of $21.00 (ranging from $17.00 to $70.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $13.39, the median forecast implies a 56.8% upside. This outlook is supported by 15 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 422.8% upside. Conversely, the most conservative target is provided by Judah Frommer at Morgan Stanley, suggesting a 27.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMPS Analyst Ratings
15
Buy
0
Hold
0
Sell
CMPS Price Target Range
Low
$17.00
Average
$21.00
High
$70.00
Current: $13.39
Latest CMPS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMPS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $70.00 |
| Jul 8, 2026 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Upgrade | $21.00 |
| Jul 8, 2026 | Stifel | Paul Matteis | Buy | Maintains | $21.00 |
| Jul 7, 2026 | Morgan Stanley | Judah Frommer | Overweight | Reiterates | $17.00 |
| Jul 7, 2026 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $20.00 |
| Jul 7, 2026 | BTIG | Thomas Shrader | Buy | Maintains | $25.00 |
| Jun 26, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 15, 2026 | Maxim Group | Buy | Maintains | $N/A | |
| May 14, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| May 14, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 13, 2026 | BTIG | Buy | Reiterates | $N/A | |
| May 4, 2026 | Jefferies | Buy | Initiates | $N/A | |
| Apr 28, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 24, 2026 | B. Riley Securities | Buy | Initiates | $N/A | |
| Apr 20, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 26, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 25, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Mar 2, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 18, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 18, 2026 | Morgan Stanley | Overweight | Maintains | $N/A |
Compass Pathways plc Depositary Receipt (CMPS) Competitors
The following stocks are similar to Compass Pathways based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Compass Pathways plc Depositary Receipt (CMPS) Financial Data
Compass Pathways plc Depositary Receipt has a market capitalization of $1.81B with a P/E ratio of -4.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -68.5%.
Valuation Metrics
Market Cap
$1.81B
Enterprise Value
$1.43B
P/E Ratio
-4.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+25.8%
Current Ratio
3.3x
Debt/Equity
16.3x
ROE
-68.5%
ROA
-25.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Compass Pathways plc Depositary Receipt (CMPS) Business Model
About Compass Pathways plc Depositary Receipt
What They Do
Biotechnology company focused on mental health innovation.
Business Model
The company generates revenue through the development and commercialization of its proprietary synthetic psilocybin therapy, COMP360, which is currently undergoing clinical trials for various mental health conditions. By addressing unmet needs in mental health care, particularly for treatment-resistant patients, it aims to create a sustainable market for its innovative therapies.
Additional Information
Compass Pathways plc was founded in 2020 and is headquartered in London, UK. It is at the forefront of the emerging field of psychedelic medicine, with a strong emphasis on evidence-based therapies for severe psychiatric conditions. The company is currently advancing its clinical trials in both the UK and the US.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
166
CEO
Mr. Kabir Kumar Nath M.A., M.B.A.
Country
United Kingdom
IPO Year
2020
Website
compasspathways.comCompass Pathways plc Depositary Receipt (CMPS) Latest News & Analysis
Latest News
Quick Summary
Compass Pathways (NASDAQ: CMPS) reported 26-week data from its Phase 3 COMP006 trial, affirming the safety and durability of its psilocybin therapy, COMP360, aiming for a U.S. launch in early 2027.
Why It Matters
Positive Phase 3 trial results enhance COMP360's prospects, signaling potential market entry and revenue growth, which could boost Compass Pathways' stock value ahead of the launch.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Compass Pathways stock declined on Tuesday, despite positive test results for its psychedelic drug aimed at treating resistant depression.
Why It Matters
The decline in Compass Pathways stock despite positive test results signals investor skepticism about future prospects, potentially affecting market confidence in the psychedelic drug sector.
Source: Investors Business Daily
Market Sentiment:
Positive
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline
8 days ago
Quick Summary
Compass Pathways plc (NASDAQ:CMPS) reported positive 26-week results from Part B of its Phase 3 COMP006 trial, highlighting the efficacy of its synthetic psilocybin therapy for treatment-resistant depression.
Why It Matters
Compass Pathways' positive Phase 3 trial results for COMP360 signal potential market success, enhancing investor confidence in the company's growth and innovation in mental health therapies.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
COMPASS Pathways plc (CMPS) reports six-month data from its second Phase 3 trial, confirming the rapid and durable efficacy of its treatment for depression.
Why It Matters
Positive Phase 3 trial results for COMPASS Pathways suggest potential for effective depression treatment, which could enhance market position and drive stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Compass Pathways (Nasdaq: CMPS) announced positive 26-week results from its Phase 3 trial of COMP360 for treatment-resistant depression, confirming its rapid onset and durable profile in nearly 600 patients.
Why It Matters
Positive Phase 3 trial results for Compass Pathways' COMP360 suggest strong efficacy for treatment-resistant depression, potentially boosting the company's stock value and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Compass Pathways received a 'Strong Buy' rating following successful COMP360 trial results and the full NDA submission for Q4.
Why It Matters
Compass Pathways' successful COMP360 trial and NDA submission signal potential for market approval, likely boosting stock value and attracting investor interest in the psychedelic therapy sector.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About CMPS Stock
What is Compass Pathways plc Depositary Receipt's (CMPS) stock forecast for 2027?
Based on our analysis of 8 Wall Street analysts, Compass Pathways plc Depositary Receipt (CMPS) has a median price target of $21.00. The highest price target is $70.00 and the lowest is $17.00.
Is CMPS stock a good investment in 2027?
According to current analyst ratings, CMPS has 15 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CMPS stock?
Wall Street analysts predict CMPS stock could reach $21.00 in the next 12 months. This represents a 56.8% increase from the current price of $13.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Compass Pathways plc Depositary Receipt's business model?
The company generates revenue through the development and commercialization of its proprietary synthetic psilocybin therapy, COMP360, which is currently undergoing clinical trials for various mental health conditions. By addressing unmet needs in mental health care, particularly for treatment-resistant patients, it aims to create a sustainable market for its innovative therapies.
What is the highest forecasted price for CMPS Compass Pathways plc Depositary Receipt?
The highest price target for CMPS is $70.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 422.8% increase from the current price of $13.39.
What is the lowest forecasted price for CMPS Compass Pathways plc Depositary Receipt?
The lowest price target for CMPS is $17.00 from Judah Frommer at Morgan Stanley, which represents a 27.0% increase from the current price of $13.39.
What is the overall CMPS consensus from analysts for Compass Pathways plc Depositary Receipt?
The overall analyst consensus for CMPS is bullish. Out of 8 Wall Street analysts, 15 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are CMPS stock price projections?
Stock price projections, including those for Compass Pathways plc Depositary Receipt, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 2:44 AM UTC